Search

Your search keyword '"Hirai, Makoto"' showing total 18 results
Start Over Author "Hirai, Makoto" Publisher japanese circulation society
18 results on '"Hirai, Makoto"'

1. Elevated Red Blood Cell Distribution Width Predicts Recurrence After Catheter Ablation for Atrial Fibrillation in Patients With Heart Failure – Comparison With Non-Heart Failure Patients –

Author

Yanagisawa, Satoshi, primary, Inden, Yasuya, additional, Kato, Hiroyuki, additional, Miyoshi, Aya, additional, Mizutani, Yoshiaki, additional, Ito, Tadahiro, additional, Kamikubo, Yosuke, additional, Kanzaki, Yasunori, additional, Hirai, Makoto, additional, and Murohara, Toyoaki, additional

Published
2016
Full Text
View/download PDF

2. Clinical Outcome of Implantable Cardioverter Defibrillators With Recalled and Non-Recalled Leads in Japanese Patients

Author

Yanagisawa, Satoshi, primary, Inden, Yasuya, additional, Shimano, Masayuki, additional, Yoshida, Naoki, additional, Ichiyanagi, Hiroshi, additional, Fujita, Masaya, additional, Ohguchi, Shiou, additional, Ishikawa, Shinji, additional, Kato, Hiroyuki, additional, Okumura, Satoshi, additional, Miyoshi, Aya, additional, Nagao, Tomoyuki, additional, Yamamoto, Toshihiko, additional, Hirai, Makoto, additional, and Murohara, Toyoaki, additional

Published
2014
Full Text
View/download PDF

5. Vagal Modification Can Also Help Prevent Late Recurrence of Atrial Fibrillation After Segmental Pulmonary Vein Isolation

Author

Yoshida, Naoki, primary, Yamada, Takumi, additional, Murakami, Yoshimasa, additional, Okada, Taro, additional, Ninomiya, Yuichi, additional, Toyama, Junji, additional, Yoshida, Yukihiko, additional, Tsuboi, Naoya, additional, Muto, Masahiro, additional, Inden, Yasuya, additional, Hirai, Makoto, additional, and Murohara, Toyoaki, additional

Published
2009
Full Text
View/download PDF

7. Increase in Electrocardiographic R-Waves After Revascularization in Patients With Acute Myocardial Infarction

Author

Isobe, Satoshi, primary, Takada, Yasuo, additional, Ando, Akitada, additional, Ohshima, Satoru, additional, Yamada, Kiyoyasu, additional, Nanasato, Mamoru, additional, Unno, Kazumasa, additional, Ogawa, Takuo, additional, Kondo, Takahisa, additional, Izawa, Hideo, additional, Inden, Yasuya, additional, Hirai, Makoto, additional, and Murohara, Toyoaki, additional

Published
2006
Full Text
View/download PDF

8. Investigation of the Optimal Treatment Strategy for Atrial Fibrillation in Japan-The J-RHYTHM (Japanese Rhythm Management Trial for Atrial Fibrillation) Study Design-

Author

Yamashita, Takeshi, primary, Ogawa, Satoshi, additional, Aizawa, Yoshifusa, additional, Atarashi, Hirotsugu, additional, Inoue, Hiroshi, additional, Ohe, Tohru, additional, Okumura, Ken, additional, Kato, Takao, additional, Kamakura, Shiro, additional, Kumagai, Koichiro, additional, Kurachi, Yoshihisa, additional, Kodama, Itsuo, additional, Koretsune, Yukihiro, additional, Saikawa, Tetsunori, additional, Sakurai, Masayuki, additional, Sugi, Kaoru, additional, Nakaya, Haruaki, additional, Nakayama, Toshio, additional, Hirai, Makoto, additional, Fukatani, Masahiko, additional, Mitamura, Hideo, additional, and Yamazaki, Tsutomu, additional

Published
2003
Full Text
View/download PDF

10. Activation - Recovery Intervals of 12-Lead Electro-cardiograms Before and After Catheter Ablation in Patients With Wolff-Parkinson-White Syndrome

Author

Nonokawa, Makoto, primary, Hirai, Makoto, additional, Akahoshi, Makoto, additional, Inden, Yasuya, additional, Yoshida, Yukihiko, additional, Ito, Teruo, additional, Yokoyama, Yumiko, additional, Sawada, Takahisa, additional, Shimizu, Atsuya, additional, Takada, Yasunobu, additional, Iino, Shigeo, additional, Kondo, Takahisa, additional, and Saito, Hidehiko, additional

Published
2001
Full Text
View/download PDF

17. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study.

Author

Ogawa S, Yamashita T, Yamazaki T, Aizawa Y, Atarashi H, Inoue H, Ohe T, Ohtsu H, Okumura K, Katoh T, Kamakura S, Kumagai K, Kurachi Y, Kodama I, Koretsune Y, Saikawa T, Sakurai M, Sugi K, Tabuchi T, Nakaya H, Nakayama T, Hirai M, Fukatani M, and Mitamura H

Subjects
Adrenergic beta-Antagonists pharmacology, Adrenergic beta-Antagonists therapeutic use, Aged, Anti-Arrhythmia Agents pharmacology, Anti-Arrhythmia Agents therapeutic use, Atrial Fibrillation ethnology, Calcium Channel Blockers pharmacology, Calcium Channel Blockers therapeutic use, Endpoint Determination, Female, Heart Conduction System drug effects, Heart Rate drug effects, Humans, Japan, Kaplan-Meier Estimate, Male, Middle Aged, Quality of Life, Sinoatrial Node drug effects, Sinoatrial Node physiopathology, Atrial Fibrillation drug therapy, Atrial Fibrillation physiopathology, Heart Conduction System physiopathology, Heart Rate physiology
Abstract

Background Although previous clinical trials demonstrated the non-inferiority of a rate control to rhythm control strategy for management of atrial fibrillation (AF), the optimal treatment strategy for paroxysmal AF (PAF) remains unclear. Methods and Results A randomized, multicenter comparison of rate control vs rhythm control in Japanese patients with PAF (the Japanese Rhythm Management Trial for Atrial Fibrillation (J-RHYTHM) study) was conducted. The primary endpoint was a composite of total mortality, symptomatic cerebral infarction, systemic embolism, major bleeding, hospitalization for heart failure, or physical/psychological disability requiring alteration of treatment strategy. In the study, 823 patients with PAF were followed for a mean period of 578 days. The primary endpoint occurred in 64 patients (15.3%) assigned to rhythm control and in 89 patients (22.0%) to rate control (P=0.0128). No significant differences between the treatment strategies were observed in the incidences of death, stroke, bleeding and heart failure. Meanwhile, significantly fewer patients requested changes of assigned treatment strategy in the rhythm control vs the rate control group, which was accompanied by improvement in AF-specific quality of life scores. Conclusion The J-RHYTHM study showed that rhythm control was associated with fewer primary endpoints than rate control. However, mortality and cardiovascular morbidity were not affected by the treatment strategy (umin-CTR No. C000000106).

Published
2009
Full Text
View/download PDF

18. Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension.

Author

Yamashita T, Ogawa S, Aizawa Y, Atarashi H, Inoue H, Ohe T, Okumura K, Ohtsu H, Kato T, Kamakura S, Kumagai K, Kurachi Y, Kodama I, Koretsune Y, Saikawa T, Sakurai M, Sugi K, Nakaya H, Hirai M, Hirayama A, Fukatani M, Mitamura H, Yamazaki T, and Watanabe E

Subjects
Amlodipine administration & dosage, Benzimidazoles administration & dosage, Biphenyl Compounds, Dihydropyridines administration & dosage, Humans, Hypertension complications, Secondary Prevention, Tetrazoles administration & dosage, Angiotensin II Type 1 Receptor Blockers administration & dosage, Atrial Fibrillation drug therapy, Calcium Channel Blockers administration & dosage, Hypertension drug therapy
Abstract

Background: Mega trials of rhythm vs rate control could not demonstrate the usefulness of available antiarrhythmic drugs, so a more effective and safer therapy for atrial fibrillation (AF) is now required. One candidate is the so-called "upstream therapy", which refers to the blockade of upstream modifying elements (renin - angiotensin system, cathecholamines, oxidative stress etc) that contribute to the arrhythmogenic substrate., Methods and Results: The Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM II study) is a randomized comparative evaluation of an angiotensin II type 1 blocker (candesartan) and a dihydropiridine calcium blocker (amlodipine), both combined with antithrombotic therapy, as an antiarrhythmic therapy for the treatment of paroxysmal AF (PAF) associated with hypertension. To test the usefulness of this therapy, this study will reveal the recurrence rate of asymptomatic as well as symptomatic PAF during 1-year of treatment with candesartan or amlodipine, using daily transtelephonic monitoring., Conclusions: The J-RHYTHM II study will follow 400 patients with PAF and hypertension who were treated at approximately 50 sites throughout Japan, and will provide clinically important information.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results